Novartis Q4 Non-GAAP EPS of $1.40 misses by $0.01, revenue of $13.23B misses by $20M

Feb. 02, 2022 2:04 AM ETNovartis AG (NVS)By: Mamta Mayani, SA News Editor6 Comments
  • Novartis press release (NYSE:NVS): Q4 Non-GAAP EPS of $1.40 misses by $0.01.
  • Revenue of $13.23B (+3.6% Y/Y) misses by $20M.
  • Cosentyx sales $1.24B, estimate $1.28B
  • Entresto sales $949M, estimate $988.3M
  • Zolgensma sales $342M, estimate $357.2M
  • Gilenya sales $656M, estimate $701.7M
  • Core operating income of $3.82B, up 9% Y/Y.
  • 2022 guidance – Group sales and core operating income expected to grow mid single digit.
  • The Novartis Board of Directors proposes a dividend payment of CHF 3.10/for 2021, up 3.3% from CHF 3.00/in prior year.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.